BioSpace News Archive

K36 Therapeutics, Inc. today announced that its abstract evaluating KTX-1001 in relapsed and refractory multiple myeloma has been accepted for presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, which will be held December 9-12, 2023, in San Diego, California, and online.

Exelixis, Inc. and Arcus Biosciences announced that the companies have entered into a clinical trial collaboration for STELLAR-009, a phase 1b/2 trial evaluating zanzalintinib, Exelixis’ next-generation tyrosine kinase inhibitor, in combination with AB521, an inhibitor of the transcription factor HIF-2⍺, in patients with advanced solid tumors, including clear cell renal cell carcinoma.

Curemark today announced the publication of their long-term clinical data demonstrating disease/disorder modification in maladaptive behaviors in children as young as 3 years of age with Autism Spectrum Disorder (ASD).

Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced a license agreement with Abbisko Therapeutics Co. Ltd., Shanghai, China, for pimicotinib (ABSK021), which is currently being evaluated in a Phase III study for the treatment of tenosynovial giant cell tumor (TGCT).

Exelixis, Inc. (Nasdaq: EXEL) today announced the initiation of STELLAR-305, a phase 2/3 pivotal trial evaluating zanzalintinib in combination with pembrolizumab versus pembrolizumab.

Centene Corporation (NYSE: CNC) (“the Company”) today announced that it will host an investor day on Tuesday, December 12, 2023.

Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that the State of Tennessee added ZTlido® as a preferred agent to the Medicaid Preferred Drug List effective as of October 1, 2023.

Nona Biosciences, a global pioneer of technology innovation and antibody discovery and development solutions, announced it has entered into a collaboration agreement with Lycia Therapeutics, a leader in extracellular protein degradation.

Supercell Biotechnology Corporation commemorates the first anniversary of rebranding from previously-called SinoCell Technologies, due to the company’s capital increase by RMT Holding Group.

XNK Therapeutics AB announced that Johan Liwing, CEO, will present the company at the DNB Nordic Healthcare Conference in Oslo, Norway, on December 14 at 10:15am CET.